Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Retro expands Phase I trial of RTR242 to 108 volunteers in Australia Retro will add two high‑dose cohorts and increase its Phase I study of RTR242 to 108 participants in Australia. The trial enrolls healthy adults aged 18–65 years. This expansion follows the initial dosing that began earlier this year. The company is adding 32 participants and two new dose‑escalation groups to better define the dose for further clinical development. These groups will help Retro select the optimal dose for subsequent trials. The move aims to pinpoint a tolerable level that can be taken forward. On August 26, CEO Joe Betts‑Lacqua told Business Insider that the study would grow from 76 to 108 volunteers. In May Retro announced the first human administration of RTR242. Since that start, the company has been expanding enrollment and raising doses. Betts‑Lacqua explained that early tolerability testing has not yet revealed an upper dose limit, so the team must find a level participants can tolerate and carry into later studies. He said, “This is for us in some sense both a curse and a blessing: because of this it’s a bit harder to assess the moment when we can say: ‘hurray, the drug works’.” Retro describes RTR242 as a small‑molecule compound that enhances autophagy — the process whereby a cell delivers damaged proteins and cellular components to lysosomes for breakdown. In lysosomes, the acidic interior degrades this cargo into reusable building blocks. The company expects RTR242 to restore lysosomal acidity and make this recycling more efficient. Full Robbins, a biochemist at the University of Minnesota, called lysosomes an intriguing target for intervention. With the additional 32 participants, Retro widens the dose range from which it will choose the level for further development of RTR242. 🔗 Read original →